Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 24;19(7):1047–1060. doi: 10.20892/j.issn.2095-3941.2020.0416

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2022, Cancer Biology & Medicine

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Hemoxylin and eosin-stained tissue sections from mice treated with UCNP-siRNA-AS1411, (A) for mice treated with phosphate-buffered saline, and (B) for 24 days of treatment. (A1, B1) spleen, (A2, B2) heart, (A3, B3) liver, (A4, B4) spleen, (A5, B5) kidney. Magnification: 100×. (C) The in vitro organ imaging of Au-siRNA-PAA-AS1411-treated mice. (D) Quantification of Lu3+ accumulation in organs by inductively-coupled plasma mass spectrometry. The data of UCNP-siRNA-AS1411 distributions in the liver, spleen, lung, kidney, and heart at 1 h and 1, 7, and 115 days after the inhalation-mediated localized delivery of UCNP nanocages. The data are expressed as the mean ± SD (n = 6; ***P < 0.005) in each study group.